{"id":7696,"date":"2025-11-06T08:00:00","date_gmt":"2025-11-06T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/"},"modified":"2025-11-06T08:12:13","modified_gmt":"2025-11-06T07:12:13","slug":"nanexa-publicerar-delarsrapport-for-januari-september-2025","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2025"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Vi har tagit viktiga steg fram\u00e5t med optimeringen av v\u00e5ra GLP-1-formuleringar och f\u00f6rl\u00e4ngt ett befintligt kommersiellt partnerskap. Vi har ocks\u00e5 f\u00e5tt godk\u00e4nnande f\u00f6r en PharmaShell-patentans\u00f6kan i Japan och l\u00e4mnat in tre nya patentans\u00f6kningar.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>V\u00e4sentliga h\u00e4ndelser under tredje kvartalet 2025<\/p>\n<ul>\n<li>Nanexa meddelade i augusti att en f\u00f6rl\u00e4ngning av utv\u00e4rderingsavtal med ett stort l\u00e4kemedelsf\u00f6retag tecknats. Syftet \u00e4r att unders\u00f6ka PhamaShell\u00ae-formuleringar med l\u00e5ngverkande effekt f\u00f6r ett specifikt l\u00e4kemedel med en aktuell \u00e5rlig f\u00f6rs\u00e4ljning p\u00e5 \u00f6ver 1 miljard USD.<\/li>\n<li>Nanexa meddelade i september att bolaget erh\u00e5llit japanskt patentgodk\u00e4nnande f\u00f6r en specifik PharmaShell-struktur.<\/li>\n<\/ul>\n<p>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/p>\n<ul>\n<li>Nanexa meddelade i oktober att bolaget byter Certified Adviser till Tapper Partners AB.<\/li>\n<li>Nanexa meddelade i oktober att bolaget har blivit utvalt som finalist i kategorin Drug Delivery Technology av den ledande branschtidningen Fierce Life Sciences.<\/li>\n<\/ul>\n<p>Finansiell \u00f6versikt<\/p>\n<p>1 juli &#8211; 30 september 2025<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 477 (6 434) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -11 983 (-4 550) kSEK<\/li>\n<li>Periodens resultat uppgick till: -12 538 (-4 438) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,08 (-0,03) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -15 483 (-12 302) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 24 779 (29 009) kSEK<\/li>\n<\/ul>\n<p>1 januari &#8211; 30 september 2025<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 6 059 (19 844) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -25 433 (-14 037) kSEK<\/li>\n<li>Periodens resultat uppgick till: -27 424 (-13 273) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,18 (-0,10) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: 14 488 (-36 160) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 24 779 (29 009) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida: <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" rel=\"noopener\" target=\"_blank\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p>Rapportkommentar 6 november kl. 10:00<\/p>\n<p>En lives\u00e4nd kommentar med vd David Westberg h\u00e5lls den 6 november kl. 10:00 via Infront Direkt Studios och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p>Rapportkommentaren kommer att finnas tillg\u00e4nglig <a href=\"https:\/\/eur01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fyoutube.com%2Flive%2F_N5xDKNmdec%3Ffeature%3Dshare&amp;data=05|02|maria.medeen%40nanexa.se|e29099de1dbc427517c108de0d6c4c7a|cf2057b571ae407dac1e06fc7f9e6904|0|0|638962956004471302|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|40000|||&amp;sdata=bHuRIPCvTB2fZfPnnQtH%2FOLYzmXOi9e5j8Wlx9kLnf4%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">h\u00e4r.<\/a><\/p>\n<p>Rapportkommentaren kommer \u00e4ven att l\u00e4ggas upp p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr\/>\n<p>David Westberg \u2013 vd, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Tapper Partners AB.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr\/>\n<p>Nanexa introducerar kontroll, precision och m\u00e5ngsidighet till l\u00e4kemedelsformuleringar med hj\u00e4lp av ALD-teknik (Atomic Layer Deposition). F\u00f6retagets patenterade PharmaShell\u00ae-plattform \u00e4r ett unikt drug delivery-system som m\u00f6jligg\u00f6r h\u00f6g drug load vilket ger l\u00e5g injektionsvolym och skapar en ny generation formuleringar, s\u00e5 kallade \u201dsuper generics\u201d som ger st\u00f6rre bekv\u00e4mlighet och minskar kostnaderna vid behandling av allehanda sjukdomstillst\u00e5nd som metabola sjukdomar, t.ex. typ 2-diabetes och obesitas, hematologi\/onkologi, hj\u00e4rt-k\u00e4rlsjukdomar, psykiatri och m\u00e5nga andra.<br \/>Nanexa utvecklar egna l\u00e4kemedelsprodukter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2025-11-06 08:00 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/28975e88-6d72-40dc-a992-d9c9c1cdbce3\/nanexa-delarsrapport-q3-rapport-2025.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa Del\u00e5rsrapport Q3 Rapport 2025<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Vi har tagit viktiga steg fram\u00e5t med optimeringen av v\u00e5ra GLP-1-formuleringar och f\u00f6rl\u00e4ngt ett befintligt kommersiellt partnerskap. Vi har ocks\u00e5 f\u00e5tt godk\u00e4nnande f\u00f6r en PharmaShell-patentans\u00f6kan i Japan och l\u00e4mnat in tre nya patentans\u00f6kningar.<\/p>\n","protected":false},"template":"","class_list":["post-7696","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q3_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2025 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2025 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Vi har tagit viktiga steg fram\u00e5t med optimeringen av v\u00e5ra GLP-1-formuleringar och f\u00f6rl\u00e4ngt ett befintligt kommersiellt partnerskap. Vi har ocks\u00e5 f\u00e5tt godk\u00e4nnande f\u00f6r en PharmaShell-patentans\u00f6kan i Japan och l\u00e4mnat in tre nya patentans\u00f6kningar.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-06T07:12:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2025\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2025\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2025 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-11-06T07:00:00+00:00\",\"dateModified\":\"2025-11-06T07:12:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2025\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2025\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2025 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2025 - Nanexa AB","og_description":"Vi har tagit viktiga steg fram\u00e5t med optimeringen av v\u00e5ra GLP-1-formuleringar och f\u00f6rl\u00e4ngt ett befintligt kommersiellt partnerskap. Vi har ocks\u00e5 f\u00e5tt godk\u00e4nnande f\u00f6r en PharmaShell-patentans\u00f6kan i Japan och l\u00e4mnat in tre nya patentans\u00f6kningar.","og_url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/","og_site_name":"Nanexa AB","article_modified_time":"2025-11-06T07:12:13+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/","url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2025 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-11-06T07:00:00+00:00","dateModified":"2025-11-06T07:12:13+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2025"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}